Simcere Pharmaceutical Group Limited (HKG:2096)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2012
Intersegment Elimination	-94.61M	-42.73M	-	-	-
Anti-oncology Business	2.02B	1.30B	-	-	-
Anti-oncology Business Growth	56.24%	-	-	-	-
Other Pharmaceutical Business	5.80B	5.38B	-	-	-
Other Pharmaceutical Business Growth	7.79%	-	-	-	-
Pharmaceuticals	-	-	6.61B	6.32B	5.00B
Pharmaceuticals Growth	-	-	4.49%	26.49%	10.89%
Total	7.73B	6.64B	6.61B	6.32B	5.00B
Total Growth	16.52%	0.41%	4.49%	26.49%	10.89%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2012
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2012
People's Republic of China (PRC)	7.73B	6.64B	6.61B	6.32B	5.00B
People's Republic of China (PRC) Growth	16.52%	0.41%	4.49%	26.49%	10.89%
Total	7.73B	6.64B	6.61B	6.32B	5.00B
Total Growth	16.52%	0.41%	4.49%	26.49%	10.89%

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 30, 2026

Data Sources Report a data error